RNA

Avidity Biosciences Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website aviditybiosciences.com
Employees(FY) 186
ISIN US05370A1088

Performance

-6.59%

-13.48%

-3.85%

+47.97%

+382.32%

YTD

+631.16%

Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of RNA 2024-11-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 30, Oscillators Score at 40, and a Technical Score of 35, suggesting a lack of upward momentum and potential weakness in the stock's performance. The combined scores indicate that caution is warranted, as the market sentiment leans towards negative.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of RNA

Stock Rank

Recent News & Updates

2024-11-14 14:16
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data(Zacks)
2024-11-14 08:36
RNA Stock Hits Record High on Entering the Cardiac Disease Space(Zacks)
2024-11-13 11:24
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News(Investor's Business Daily)
2024-11-12 07:00
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations(PR Newswire)
2024-11-11 18:00
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations(Prnewswire)
2024-11-09 09:34
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag(Simply Wall St.)
2024-11-07 18:10
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates(Zacks)
2024-11-07 16:05
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights(PR Newswire)
2024-11-07 03:05
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights(Prnewswire)
2024-11-06 10:00
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for(Zacks)
2024-11-06 04:27
An RNAi renaissance is creating a new generation of startups(BioPharma Dive)
2024-10-31 09:00
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024(PR Newswire)
2024-10-30 21:00
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024(Prnewswire)
2024-10-30 08:00
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy(PR Newswire)
2024-10-29 20:00
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy(Prnewswire)
2024-10-21 16:05
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(PR Newswire)
2024-10-21 04:05
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Prnewswire)
2024-10-18 08:00
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up(Investor's Business Daily)
2024-10-09 17:27
Avidity Biosciences Insider Sold Shares Worth $1,349,259, According to a Recent SEC Filing(MT Newswires)
2024-10-04 19:00
Why Avidity Biosciences Zoomed to a 12% Gain This Week(Motley Fool)
2024-10-04 10:53
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial(Pharmaceutical Technology)
2024-10-03 09:12
Sector Update: Health Care Stocks Steady Premarket Thursday(MT Newswires)
2024-10-03 08:13
Avidity Biosciences Says FDA Lifted Partial Hold on Investigational Therapy for Neuromuscular Disease(MT Newswires)
2024-10-03 07:00
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)(PR Newswire)
2024-10-02 19:00
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)(Prnewswire)
2024-09-29 06:27
Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?(Insider Monkey)
2024-09-26 19:34
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?(Insider Monkey)
2024-09-25 09:00
Avidity Biosciences to Participate in Upcoming Investor Conference(PR Newswire)
2024-09-24 21:00
Avidity Biosciences to Participate in Upcoming Investor Conference(Prnewswire)
2024-09-24 06:05
Goldman Sachs Initiates Avidity Biosciences at Buy(MT Newswires)

Page 1 of 9

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.